SGLT2 Inhibitors and Cancer: What's the Risk?


The 3 FDA-approved sodium glucose co-transporter 2 inhibitors remain under close post-marketing scrutiny. These 7 slides distill for you all the cancer risk information to date.

There are 3 sodium glucose co-transporter 2 inhibitors approved for use in the US in patients with type 2 diabetes. Dapagliflozin, canagliflozin, and empagliflozin have all come under increased FDA scrutiny for potential carcinogenicity and manufacturers are engaged in mandatory post-marketing studies to further current understanding.The brief slide show above distills the clinical data on cancer risk for the 3 SGLT2 inhibitors. References for all slides are provided below.


Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.